The research-driven pharmaceutical company Boehringer Ingelheim has announced changes in its Board of Managing Directors. 

Allan Hillgrove, Member of the Board of Managing Directors responsible for the Human Pharma and the Biopharma business, will step down from the Board and retire at the end of this year after 37 committed and successful years within the corporation.

The shareholders have decided to appoint Dr Carine Brouillon to the Board of Managing Directors, effective January 1st, 2020 as his successor. Since she joined Boehringer Ingelheim in 2018, Carine Brouillon has been leading the Therapeutic Areas for prescription medicines.

Also at the end of this year, Dr Joachim Hasenmaier will retire and step down as member of the Board of Managing Directors and from his responsibility for the Animal Health business. 

The shareholders have decided to appoint Jean Scheftsik de Szolnok as Member of the Board of Managing Directors and new Head of the Animal Health Business Unit, effective January 1st, 2020. 

Also, Dr Andreas Neumann has decided to step down from the Board of Managing Directors at the end of September and will leave the corporation after more than eight years of dedicated work for the corporation.